Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8402243 | 1.00 | CYP2C9 (0.50) | CYP2C9SMN1; SMN2GAAHPGDNPSR1 | |
| SCHEMBL12295563 | 1.00 | CYP2C9 (0.50) | CYP2C9SMN1; SMN2GAAHPGDNPSR1 | |
| SCHEMBL21790675 | 0.85 | CYP2C9 (0.46) | CYP2C9SMN1; SMN2GAAHPGDNPSR1 | |
| SCHEMBL22304296 | 0.82 | CYP2C9 (0.48) | CYP2C9MEN1KMT2AALDH1A1PSMB5 | |
| SCHEMBL26332579 | 0.80 | HDAC3 (0.48) | SMN1; SMN2GAAHPGDNPSR1L3MBTL1 | |
| SCHEMBL26022388 | 0.80 | CYP2C9 (0.46) | CYP2C9SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL13975597 | 0.80 | CYP2C9 (0.46) | CYP2C9SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL20732426 | 0.79 | ALDH1A1 (0.42) | CYP2C9SMN1; SMN2GAAHPGDNPSR1 | |
| SCHEMBL13125725 | 0.79 | CYP2C9 (0.50) | CYP2C9HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL155431 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655239-B2 | Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof | Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-09 | — | — | US | disclosed |
| US-8841331-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8338441-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338441-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2010130034-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230077316-A1 | CTPS1 INHIBITORS AND USES THEREOF | CTPS1, CTPS2, ECHS1 | CYP2C9 872/4885SMN1; SMN2 3045/4885GAA 421/4885 |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | CYP2C9 2388/4885SMN1; SMN2 4172/4885GAA 2055/4885 |
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | CYP2C9 3956/4885SMN1; SMN2 2490/4885GAA 193/4885 |
| US-11655239-B2 | Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof | DDR2, DDR1, DOCK2 | CYP2C9 2276/4885SMN1; SMN2 1738/4885GAA 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.